Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 4/20 | 0.48 |
| ▸ | USP19 | O94966 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14746402 | 0.82 | USP7 (0.48) | USP7USP19TSHRLMNAHSD17B10 | |
| SCHEMBL14743412 | 0.78 | USP7 (0.76) | USP7USP19ALDH1A1GAA | |
| SCHEMBL14735378 | 0.70 | USP7 (0.62) | USP7USP19 | |
| SCHEMBL14735440 | 0.65 | USP7 (1.00) | USP7USP19 | |
| SCHEMBL9402288 | 0.62 | CYP2C19 (0.70) | LMNARAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL14947107 | 0.62 | CYP2C19 (0.70) | LMNARAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL16683907 | 0.62 | CYP2C19 (0.70) | LMNARAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5831753 | 0.60 | CYP2C19 (0.61) | LMNARAB9AALDH1A1MAPTHPGD | |
| SCHEMBL31561611 | 0.60 | CYP2C19 (0.57) | LMNARAB9AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL17330308 | 0.60 | ACE (0.55) | LMNAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751092-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2014-07-09 | — | — | EP | claimed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | claimed |
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | HYBRIGENICS SA (FR) | 2014-12-18 | — | — | US | disclosed |
| EP-2751092-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Hybrigenics S.A. (FR) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013030795-A1 | PROCESS FOR THE PRODUCTION OF A FLAME RETARDANT COMPOSITION | R&D INNOVACTION S.R.L. (IT) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030218-A1 | SELECTIVE AND REVERSIBLE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | HYBRIGENICS SA (FR) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371247-A1 | Selective and Reversible Inhibitors of Ubiquitin Specific Protease 7 | USP7, UBA7, SENP7 | USP7 1/4885USP19 20/4885TSHR 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.